

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2025/011407 A1

(43) International Publication Date
16 January 2025 (16.01.2025)

(51) International Patent Classification:

A61K 8/34 (2006.01) *A61Q 19/00* (2006.01)
A61K 8/30 (2006.01) *A61P 17/00* (2006.01)
A61Q 19/02 (2006.01)

(21) International Application Number:

PCT/CN2024/103340

(22) International Filing Date:

03 July 2024 (03.07.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/512421 07 July 2023 (07.07.2023) US

(71) Applicant: **CALIWAY BIOPHARMACEUTICALS CO., LTD.** [CN/CN]; 32F, -9, No. 99, Sec. 1, Xintai 5th Rd., Xizhi Dist., New Taipei City, Taiwan 221 (CN).

(72) Inventor: **LING, Yufang**; 32F, -9, No. 99, Sec. 1, Xintai 5th Rd., Xizhi Dist., New Taipei City, Taiwan 221 (CN).

(74) Agent: **LUNG TIN INTELLECTUAL PROPERTY AGENT LTD.**; 18th Floor, Tower B, Grand Place No. 5 Huizhong Road, Chaoyang District, Beijing 100101 (CN).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: PHARMACEUTICAL COMPOSITIONS FOR USE IN REDUCING HYPERPIGMENTATION

(57) Abstract: A method for reducing hyperpigmentation in a subject, comprising administering an effective amount of a pharmaceutical composition to a skin site of a subject in need thereof, wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier and a stilbene compound, for example, a compound of Formula (I) (e.g., Formula (I-A)), or a pharmaceutically acceptable salt thereof.



WO 2025/011407 A1